ArticleFrontiers in pediatrics2025
Eosinophilic Esophagitis: real-life outcomes over 10 years in a Canadian pediatric centre.
Article in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Despite Eosinophilic Esophagitis (EoE) being a chronic condition, many studies focus on the short-term. This study characterizes patients, treatment effectiveness and outcomes in a pre-biologic era. Methods: This cohort study (2012-2022) at British Columbia (BC) Children's Hospital in Vancouver, Canada analyzed data from the EoE Registry which was hosted on Research Electronic Data Capture (REDCap) for participating patients <18 years with biopsy-proven diagnosis (≥15 eosinophils/hpf) including demographics, symptoms, allergic history, medications, endoscopy and histology. Results: 247 patients (71.2% White, 16.7% South Asian, 78.1% male, median age 9 years) were followed over a median 3-year follow up. 85.2% had at least one atopic condition and 17.4% reported Cow's Milk Protein Allergy in infancy. 19.0% lacked follow up endoscopy and in clinic follow-up, 18.2% were on no therapy. At last endoscopy of those on treatment ( Conclusions: This Canadian study reveals remission rates lower than short term studies, but a reduction in strictures in follow-up. Real-life challenges, such as not returning for follow up endoscopy (∼20%), despite no direct care costs, challenges with adherence with ∼20% not taking any therapy and over half not taking medications as prescribed contribute towards remission rates below 50% regardless of treatment. Better patient engagement, addressing barriers to treatment and follow up and exploring novel therapies are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.